A+ R A-

Therapeutics in WM: Update on Nucleoside Analogue Trials

Please select from the following list of abstracts, representing the presentations given in Paris 2004 (IWWM-3) Session 7:

The WML Trial, An International Collaborative Phase III Study Of Chlorambucil Versus Fludarabine As Initial Therapy For Waldenstrom’s Macroglobulinaemia And Related Disorders. S A Johnson, R G Owen, D G Oscier, V Leblond, V Levy, U Jaeger, J F Seymour.

Treatment Of Waldenström Macroglobulinemia With The Combination Of Fludarabine (Famp) And Cyclophosphamide (Cy): Results In 49 Patients (Pts). V Leblond, J Tamburini, V.Lévy, JP Fermand, C. Chateilex, L. Stalniewicz, P. Morel, A. Delmer, F. Dreyfus, MJ. Grange, B. Christian.

Fludarabine Combination Therapy is Highly Effective in Frontline and Salvage Treatment of Patients with Waldenstrom's Macroglobulinemia. Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF.

Combination Therapy With Rituximab And Fludarabine In Waldenstrom's Macroglobulinemia. Steven P Treon, Andrew Branagan, Parveen Wasi, Christos A Emmanouilides, Stanley R Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Sari Heitner Enschede and Eva Kimby.

Pentostatin, Cyclophosphamide And Rituximab: An Effective Regimen For Patients With Waldenström’s Macroglobulinemia. Manfred Hensel, Matthias Villalobos, Martin Kornacker, Fatime Krasniqi.

Management Of Waldenstrom’s Macroglobulinemia (WM) In The Pre-Rituximab Era: Update On US Intergroup Trial S 9003 The Arkansas Autotransplant Experience. Athanasios Fassas, Madhav Dhodapkar, Jason McCoy, Erik Rasmussen, John Crowley and Bart Barlogie.